Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tharimmune, Inc. (NASDAQ: THAR) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission, including its Current Reports on Form 8-K, proxy materials, and other registration documents. These filings provide primary-source detail on Tharimmune’s clinical-stage biotechnology programs and its Canton Coin-focused digital asset treasury strategy.
Recent Form 8-K filings describe material definitive agreements such as securities purchase agreements for private placements involving common stock and pre-funded warrants, as well as an at-the-market sales agreement for common stock. They also outline the structure and intended use of proceeds from offerings designed to support both Tharimmune’s historical biotech operations and the establishment of a Canton Coin treasury and related Canton Network participation.
Other 8-Ks and proxy materials detail corporate governance and compensation matters, including amendments to the certificate of incorporation to increase authorized common stock, changes to the omnibus equity incentive plan, and the appointment of key executives such as the Chief Executive Officer, President, and Chief Financial Officer. These documents specify employment agreement terms, severance provisions, and equity award structures for senior leadership associated with the company’s biotechnology and digital asset initiatives.
Investors can also use this page to access risk factor discussions related to Tharimmune’s Canton Coin strategy, as described in its filings, including risks tied to digital asset volatility, regulatory uncertainty, and liquidity considerations. Proxy statements provide additional context on share authorization proposals and future offering authorizations under Nasdaq rules.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, capital structure changes, and leadership updates, helping readers quickly interpret complex legal and financial language. From here, you can review Tharimmune’s 8-Ks, registration statements, and proxy materials, and use the platform’s tools to track insider-related disclosures and ongoing financing arrangements as they appear in the EDGAR feed.
Canton Strategic Holdings, Inc. entered into an amended and restated at-the-market sales agreement with Clear Street LLC and Virtu Americas LLC to sell shares of its common stock from time to time. The agreement provides for an aggregate gross sales price of up to
Sales will be made under the company’s effective Form S‑3 shelf registration and related prospectus supplement, through at-the-market transactions, negotiated deals or block trades, as permitted by law. The sales agents will use commercially reasonable efforts, earn commissions of up to
Canton Strategic Holdings, Inc. is registering an at-the-market offering to sell up to $300,000,000 of its common stock under an amended Sales Agreement with Clear Street LLC and Virtu Americas LLC, permitting sales from time to time through or to the Sales Agents.
The program amends an earlier ATM arrangement, follows prior issuances including a January registered offering and a November PIPE, and permits negotiated or Rule 415(a)(4) at-the-market sales with commissions up to 3.0% of gross proceeds; timing and amounts sold are subject to the Sales Agreement terms.
Canton Strategic Holdings, Inc. reported that its Chairman and Chief Executive Officer, Mark Wendland, has been elected to the Board of Directors of the Canton Foundation. This is described as underscoring the company’s leadership role in helping accelerate institutional adoption of the Canton Network.
The Canton Foundation is the independent governance body overseeing operation, standards, the validator framework, and policies related to the Global Synchronizer and broader Canton Network operations. With Wendland joining 17 existing Board members from major global financial institutions, Canton Strategic Holdings also becomes a Premier Member of the Foundation, deepening its alignment with the Foundation’s mission to support growth and governance of the Canton Network.
Canton Strategic Holdings, Inc., formerly Tharimmune, Inc., has completed a corporate rebrand to align with its digital asset treasury strategy focused on the Canton Network. The company changed its legal name and amended its charter and bylaws, and its NASDAQ ticker is moving from “THAR” to “CNTN” effective February 18, 2026.
The press release highlights that the company was established in November 2025 through a $545 million private placement and is pursuing value creation via Canton Coin acquisition, operating a Super Validator, and investing in applications that support institutional adoption of the Canton Network. Recent milestones include approval as a Super Validator, additions of institutional leaders such as former CFTC Commissioner Jill Sommers and DRW Chief of Staff William Wiley to the board, and closing a $55 million underwritten registered offering to fund further growth. The company also continues to operate clinical-stage biotech research and development alongside its digital asset activities.
Tharimmune, Inc. officer Angela Dominy Radkowski, the company’s Chief Operating Officer, filed an initial insider ownership report. As of the event date of 02/05/2026, she reports that no Tharimmune securities are beneficially owned. The filing is made solely by this one reporting person.
Tharimmune, Inc. director Jill E. Sommers filed a Form 3 reflecting her status as a director and indicating that she beneficially owns no securities of Tharimmune. The filing is dated for an event on January 30, 2026 and is filed by one reporting person.
Tharimmune, Inc. director William Thomas Wiley Jr. filed an initial ownership report stating that he beneficially owns no securities of the company as of the event date of January 30, 2026. The filing lists no non-derivative or derivative holdings and reports no transactions.
Tharimmune, Inc. executive Jacob Asbury, the company’s Chief Financial Officer, filed an initial ownership report on Form 3. The filing states that no securities of Tharimmune are beneficially owned, meaning he reported holding no company shares or derivative securities as of the reported event date.
Tharimmune, Inc. received a beneficial ownership report from Broadridge Financial Solutions, Inc., which now reports control over 4,187,548 shares of Tharimmune common stock through warrants exercisable within sixty days. This represents 9.99% of Tharimmune’s common stock, calculated using 37,729,847 shares outstanding as of January 17, 2026 plus the warrant shares.
The warrants are subject to a 9.99% ownership blocker in a Subscription Agreement, so an additional 13,070,680 shares issuable under the warrants are not counted in Broadridge’s beneficial ownership. The securities are owned of record by Broadridge Securities Processing Solutions, LLC, with Broadridge Financial Solutions, Inc. holding voting and dispositive power, and the filing states the stake is held on a passive, non‑control basis.
Tharimmune, Inc. appointed Angela Dominy Radkowski as Chief Operating Officer effective February 5, 2026, under an employment agreement providing a $300,000 annual base salary and an annual cash bonus target of $100,000, plus potential time- and performance-based equity awards.
The Board also elected CEO Mark Wendland as Chairman, with former Chairman Vincent LoPriore remaining on the Board, and refreshed its Audit, Compensation, and Nominating & Corporate Governance committee memberships. Nasdaq notified the company on February 2, 2025 that it had regained compliance with the Board Independence Rule after electing two independent directors on January 30, 2026.